

The Medical Letter[®]

on Drugs and Therapeutics

Volume 64

June 13, 2022

ISSUE No.
1652

IN THIS ISSUE

COVID-19 Update: FDA Narrows EUA for the Johnson & Johnson Vaccine.....p 95

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)
or call customer service at: 800-211-2769

The Medical Letter®

on Drugs and Therapeutics

Volume 64 (Issue 1652)

June 13, 2022

COVID-19 UPDATE

FDA Narrows EUA for the Johnson & Johnson Vaccine

The FDA has restricted its Emergency Use Authorization for the adenovirus-based COVID-19 vaccine manufactured by Johnson & Johnson (Janssen) to adults who are unable or unwilling to receive another COVID-19 vaccine. The mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (*Comirnaty*) and Moderna (*Spikevax*) are preferred for all persons without a contraindication.^{1,2}

The EUA was revised because of the risk of thrombosis with thrombocytopenia syndrome (TTS) associated with the Johnson & Johnson vaccine. In an analysis of submissions to its Vaccine Adverse Event Reporting System (VAERS), the FDA identified 60 confirmed cases of TTS following administration of the vaccine (3.23 cases per million doses), 9 of which were fatal (0.48 deaths per million doses). Cases were reported most frequently in females 30-49 years old (~8 cases per million doses).^{1,3}

According to CDC guidelines, **immunocompetent persons** who already received a primary dose of the Johnson & Johnson vaccine should generally receive a booster dose of an mRNA vaccine (Pfizer 30 mcg or Moderna 50 mcg) ≥ 2 months later; a second mRNA vaccine booster given ≥ 4 months after the first can be considered in patients ≥ 50

years old. Those who received both a primary and a booster dose of the Johnson & Johnson vaccine may receive a booster dose of an mRNA vaccine ≥ 4 months after their second Johnson & Johnson vaccine dose.²

Moderately or severely immunocompromised persons who have received 1 or 2 doses of the Johnson & Johnson vaccine should continue their vaccination series with an mRNA vaccine until they have received 3 total vaccine doses. An mRNA vaccine should be given ≥ 4 weeks after an initial Johnson & Johnson vaccine dose and/or ≥ 2 months after a second dose of any COVID-19 vaccine. If the completed series will include only one mRNA vaccine dose, it should be with the dose used for a primary dose (Pfizer 30 mcg or Moderna 100 mcg). If the completed series will include 2 mRNA vaccine doses, one should be a primary dose and the other a booster dose. In either case, an additional mRNA booster dose given ≥ 4 months after the third vaccine dose can also be considered.² ■

1. FDA News Release. Coronavirus (COVID-19) update: FDA limits use of Janssen COVID-19 vaccine to certain individuals. May 5, 2022. Available at: <https://bit.ly/37TG5Qh>. Accessed May 23, 2022.
2. CDC. Interim clinical considerations. Use of COVID-19 vaccines in the United States. April 21, 2022. Available at: <https://bit.ly/38i7CIH>. Accessed May 23, 2022.
3. FDA. Fact sheet for healthcare providers administering vaccine (vaccination providers). Emergency Use Authorization (EUA) of the Janssen COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). May 5, 2022. Available at: <https://bit.ly/3e6KEaD>. Accessed May 23, 2022.

PRESIDENT: Mark Abramowicz, M.D.; **VICE PRESIDENT:** Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School **VICE PRESIDENT, EDITOR IN CHIEF:** Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhM, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli

EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:

The Medical Letter, Inc.
145 Huguenot St. Ste. 312
New Rochelle, NY 10801-7537
www.medicalletter.org

Customer Service:

Call: 800-211-2769 or 914-235-0500
Fax: 914-632-1733
E-mail: custserv@medicalletter.org

Permissions:

To reproduce any portion of this issue,
please e-mail your request to:
permissions@medicalletter.org

Subscriptions (US):

1 year - \$159; 2 years - \$298;
3 years - \$398. \$65 per year
for students, interns, residents,
and fellows in the US and Canada.
Reprints - \$45 per issue or article

Site License Inquiries:

E-mail: SubQuote@medicalletter.org
Call: 800-211-2769
Special rates available for bulk
subscriptions.

Get Connected:    

Copyright 2022. ISSN 0025-2859

The
Medical
Letter